1-9 of 9
Bilal Piperdi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract LB-397: Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: analysis of KEYNOTE-189 by STK11 and KEAP1 status

Shirish M. Gadgeel, Delvys Rodriguez-Abreu, Enriqueta Felip, Emilio Esteban, Giovanna Speranza, Martin Reck, Rina Hui, Michael Boyer, Edward B. Garon, Hidehito Horinouchi, Razvan Cristescu, Deepti Aurora-Garg, Andrey Loboda, Jared Lunceford, Julie Kobie, Mark Ayers, Bilal Piperdi, M. Catherine Pietanza, Marina C. Garassino
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): LB-397.
DOI: https://doi.org/10.1158/1538-7445.AM2020-LB-397
Published: 15 August 2020
View article
Journal Articles

Abstract CT084: Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC

Byoung Chul Cho, Gilberto Lopes, Dariusz M. Kowalski, Kazuo Kasahara, Yi-Long Wu, Gilberto Castro, Hande Z. Turna, Razvan Cristescu, Deepti Aurora-Garg, Andrey Loboda, Jared Lunceford, Julie Kobie, Mark Ayers, M. Catherine Pietanza, Bilal Piperdi, Tony S. Mok
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): CT084.
DOI: https://doi.org/10.1158/1538-7445.AM2020-CT084
Published: 15 August 2020
View article
Journal Articles

Abstract CT103: Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028

Evan W. Alley, L. Rhoda Molife, Armando Santoro, Kim Beckey, Sammy Yuan, Jonathan D. Cheng, Bilal Piperdi, Johannes H.M. Schellens
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): CT103.
DOI: https://doi.org/10.1158/1538-7445.AM2015-CT103
Published: 01 August 2015
View article
Journal Articles

Abstract 3526: The mTORC2 component RICTOR plays a key role in lung cancer cell growth

Haiying Cheng, Yiyu Zou, Alain Borczuk, Wanglong Qiu, Bilal Piperdi, Mimi Kim, Balazs Halmos, Roman Perez-Soler‎
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 3526.
DOI: https://doi.org/10.1158/1538-7445.AM2014-3526
Published: 01 October 2014
View article
Journal Articles

Abstract 683: Toxicity of aerosolized azacytidine (Vidaza) in mice.

Xuan Qiu, Rani Sellers, Yuanxin Liang, Bilal Piperdi, Roman Perez-Soler, Yiyu Zou
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 683.
DOI: https://doi.org/10.1158/1538-7445.AM2013-683
Published: 15 April 2013
View article
Journal Articles

Abstract 2033: Identification of a novel genetic abnormality, the amplification of rictor (rapamycin-insensitive companion of mTOR), in a patient with non-small cell lung cancer.

Haiying Cheng, Bilal Piperdi, Edward L. Schwartz, Changcheng Zhu, Zhenfeng Zhang, Balazs Halmos, Vincent Miller, Roman Perez-Soler
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 2033.
DOI: https://doi.org/10.1158/1538-7445.AM2013-2033
Published: 15 April 2013
View article
Journal Articles

Abstract 850: Activation of autophagy by erlotinib protects NSCLC cells with wild-type EGFR from erlotinib cytotoxicity

Edward L. Schwartz, Yi-He Ling, Yiyu Zou, Bilal Piperdi, Roman Perez-Soler
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 850.
DOI: https://doi.org/10.1158/1538-7445.AM2012-850
Published: 15 April 2012
View article
Journal Articles

Abstract 1803: Phase I/II study of bortezomib in combination with carboplatin and bevacizumab as first line therapy in patients with advanced non-small cell lung cancer (NSCLC)

Bilal Piperdi, Kendra J. Bradley, Venu Bathini, Colleens M. Zekos, Meredith Hanrahan-Boshes, William V. Walsh
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 1803.
DOI: https://doi.org/10.1158/1538-7445.AM10-1803
Published: 15 April 2010
View article
Journal Articles

Schedule-dependent interaction between the proteosome inhibitor, bortezomib, and the EGFR-PTK inhibitor, erlotinib, in human non-small cell lung cancer cell lines

Bilal Piperdi, Yi-He Ling, Roman Perez-Soler
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 927.
Published: 01 April 2004
View article